SBIR/STTR Research Award

X-Ray Scattering Bone Densitometry

Award identifier 7c91adc1dbeddc59a795b93242584e7418ecffd4f7fa1eaaef439e3e420b5f7cAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$132,000

Program and phase

SBIR · Phase I

Award year

2006

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
APPLIED QUANTUM MEDICAL CORPORATION
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2006-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Osteoporosis is a serious public health problem faced by an aging US population. In past decades, there has been significant progress, as well as controversy, in the diagnosis and treatment of osteoporosis. Until recently, bone screening was inaccurate and fracture risk was difficult to calculate. A new diagnostic technique of measuring bone mineral density (BMD) for diagnosis and monitoring the course of treatment (assessment) of osteoporosis and other bone diseases is proposed. The simple and robust measurements of small-angle forward-to-backward scattering and small angle forward scattering-to-transmitted radiation, based on the use of the conventional Coherent to Compton Scattering Ratio (CCSR), can offer a high quality in-vivo measurement of BMD by overcoming prior CCSR limitations, such as high radiation dosage, high system cost and long examining time. Among radiological and other bone diagnostic technologies, CCSR is considered to be a superior and more sensitive method for BMD determination without the need for a case by case calibration. It also has several advantages over the current gold standard technology, Dual-energy X-ray Absorptiometry (DEXA). CCSR is unique in that it provides a quantitative and direct determination of volumetric BMD (in mg/cm3), the "true" density, while the areal BMD (in mg/cm2) that is obtained from DEXA, yields a highly uncertain volumetric density. Another important advantage of CCSR is that it has been accurately applied to trabecular bone in-vivo to yield Trabecular Bone Mineral Density (TBMD) which can be difficult to isolate from cortical bone in some applications of DEXA. Since trabecular bone is the most metabolically active component of the skeleton and can limit bone strength in serious fractures such as those of the hip and spine, the determination of volumetric TBMD is crucial for diagnosis and monitoring of the treatment of osteoporosis and other metabolic bone diseases. Despite the potential and promise of CCSR, it has only been applied in-vivo to the calcaneus using an obsolete configuration. The new approach used in this proposal, will demonstrate that a CCSR-based device is not only highly sensitive and accurate, but also clinically practical and useful to meet the current and future demands of osteoporosis assessment and management.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.